Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Utilities Select Sector SPDR Fund — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Utilities Select Sector SPDR Fund trades at $41.9 (market cap $24.20B). The key difference: Utilities Select Sector SPDR Fund is far larger — about 3.2× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Utilities Select Sector SPDR Fund for 81 Days on average.
| SYRE | XLU | |
|---|---|---|
Market Cap | $7.52B | $24.20B |
Volume | 1,441,031 | 27,226,247 |
Sector | Health | — |
52-Week High | $108.92 | $47.73 |
52-Week Low | $22.18 | $39.25 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
XLU trades at $41.87, up 0.58% on the day, but remains under pressure after hitting recent 52-week lows near $39.13. Technical indicators show mixed signals with a bullish moving average trend but bearish oscillators, including an overbought RSI. The utilities sector faces headwinds from rising interest rates and regulatory challenges, particularly affecting data-center demand growth.
The outlook remains cautious as utility stocks face macro pressures from interest rates and regulatory uncertainty. While defensive characteristics provide some stability, near-term performance depends on interest rate direction and AI power demand evolution. Risk-reward appears balanced with potential for recovery if macro conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
